| Nombre | MIGUEL ANGEL ALVAREZ AVITIA |
|---|---|
| Área | MEDICINA Y CIENCIAS DE LA SALUD |
| Campo | MEDICINA Y CIENCIAS DE LA SALUD |
| Disciplina | ONCOLOGÍA, QUIMIOTERAPIA, CIRUGÍA ONCOLOGÍA |
| Especialidad | ONCOLOGIA |
| CVU | 289531 |
| Institución | |
|---|---|
| Dependencia | DIVISION MEDICA |
| Entidad | CIUDAD DE MEXICO |
| Nivel | 1 |
| Vigencia | Inicio: 01/01/2025 |
| Fin: 31/12/2029 |
Publicaciones ORCID
- 2026
- When germ cell tumors defy gender: three cases of primary mediastinal presentation in women Indian Journal of Thoracic and Cardiovascular Surgery
- 2025
- Poorly differentiated ceruminous adenocarcinoma of the external auditory canal: Letter to the editor Oral Oncology
- Management of supraglottic tumors using carbon dioxide laser International Journal of Otorhinolaryngology and Head and Neck Surgery
- 2024
- Prognostic value of artificial intelligence (AI) –driven tumor estimation of PSMA PET total tumor burden (TTB) in newly diagnosed high-volume metastatic hormone-sensitive prostate cancer (mHSPC). Journal of Clinical Oncology
- 2023
- Mortality Prognosis Factors in Patients with Active Cancer Under Treatment, and Severe COVID-19 Archives of Medical Research
- Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651 Journal of Clinical Oncology
- 2022
- Multitarget Molecular Imaging in Metastatic Castration Resistant Adenocarcinoma Prostate Cancer with Therapy Induced Neuroendocrine Differentiation Diagnostics
- Prognostic factors associated with malignant somatic transformation (MST) of germ cell tumors (GCT) in a Mexican cohort: The experience of the Instituto Nacional de Cancerología, Mexico (NCIM). Journal of Clinical Oncology
- 2021
- LBA36 Nivolumab (N) + ipilimumab (I) vs EXTREME as first-line (1L) treatment (tx) for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Final results of CheckMate 651 Annals of Oncology
- Oligoprogression After Immunotherapy and Targeted Therapy in Metastatic Melanoma September 2021
